customcolor_logo_transparent_background-White-2
customcolor_icon_transparent_background-white

Join Us

If you are a positive-minded individual with a Master's or PhD degree and possess excellent writing skills, we invite you to join our OncoMotive subgroup today.

Benefits of working with us:

  1. Research Collaboration and Project Leadership:

    • Premium Members actively drive our projects, collaborating with Student Members to achieve impactful publications.
    • Gain hands-on experience in project management and leadership within the Cancer Discovery Network.

  2. Supervised Learning from Experts:

    • Premium Members receive direct supervision from our esteemed Faculty Members, ensuring personalized guidance and mentorship.
    • Benefit from the vast experience and expertise of our Faculty Members in the field of cancer biology.

  3. Authorship Opportunities:

    • Adhering to Cancer Discovery Network's academic structure, Premium Members have the chance to become first authors on published papers.
    • Faculty Members serve as corresponding authors, further elevating your profile within the academic community.

  4. Inclusive Learning Environment:

    • Open to students and researchers passionate about cancer biology, regardless of their academic background.
    • Learn from experienced supervisors, fostering an inclusive and collaborative learning environment.

  5. Training for Success:

    • Gain knowledge and skills essential for excelling in cancer research.
    • Benefit from comprehensive training programs designed to equip you for success, irrespective of your academic background.

  6. Research Opportunities:

    • Collaborate with our team to contribute to groundbreaking research and have your work published in high-impact journal articles.
    • Imagine the satisfaction of seeing your contributions recognized and celebrated in the academic community.

  7. Building a Strong Research Portfolio:

    • Join an environment that fosters collaboration, creativity, and innovation in cutting-edge cancer research projects.
    • Your contributions will be acknowledged and celebrated, helping you build a robust and distinguished research portfolio

Ask us how you can join

Research Priorities & Subgroups

www.politico

FDA Watch Subgroup

The FDA Watch Subgroup keeps a close eye on the decisions made by the U.S. Food and Drug Administration (FDA) about which drugs get approved and which get withdrawn. They pay extra attention to drugs used in cancer treatment, especially those that boost the immune system.

If the FDA decides to take back its approval for a cancer drug, this subgroup looks into why. They consider how this decision affects patients, doctors, and the drug companies, especially for specific types of cancer.

They also stress the importance of regularly checking if drugs are still safe and effective, especially when it comes to the immune system and how drugs move through the body. They stay updated on new developments in cancer treatment, like better ways to design drugs and target cancer cells, which could lead to improved treatments in the future.

research32
maxresdefault

Advanced Bioinformatics

Welcome to our High-Tech Bioinformatics Subgroup! In 2024, our research endeavors are fueled by innovation and focused on cutting-edge technologies. We have identified three priority areas that drive our projects and shape the future of bioinformatics.

1) AI-based Bioinformatics: Artificial Intelligence (AI) is revolutionizing the field of bioinformatics. We're at the forefront of harnessing AI's power to analyze biological data. By employing machine learning algorithms, we can uncover hidden patterns, make predictions, and gain profound insights into complex biological processes.

2) Single-Cell Analytic Study: Understanding biology at the single-cell level is crucial. Our research delves into single-cell analytics, a field that allows us to dissect and analyze individual cells with precision. This approach unveils intricate details of cellular behavior, aiding in disease understanding, drug development, and personalized medicine.

3) Transferable AI Models: Collaboration and knowledge sharing are essential in today's scientific landscape. We're seeking individuals well-versed in building transferable AI models. These models can be applied across various biological datasets and domains, enhancing the efficiency and effectiveness of research.

Join us on this exciting journey into the future of bioinformatics. Together, we'll push the boundaries of knowledge, advance scientific discovery, and make a lasting impact on the world of biology.

Antibody Subgroup

Monoclonal antibodies (mAbs) have revolutionized the field of pharmacy and oncology by offering highly targeted therapies for various diseases, including cancer. These antibodies are designed to bind to specific molecules or receptors on the surface of cancer cells, which can have several important implications in cancer treatment.

This special subgroup is all about creating custom-made antibodies (mAbs) for exciting new targets in cancer research. We explore and find new markers and pathways for different types of cancer. Using the latest technology, we make these antibodies super precise and good at targeting these unique markers. We test them carefully before trying them out on patients in clinical trials. Our goal is to change the way we treat cancer by making super-targeted therapies. We're dedicated to making cancer research better and giving people more effective and personalized treatments that are easier to handle.

Several monoclonal antibodies have been approved for the treatment of cancer, and they play crucial roles in the management of various cancer types. Here are a few notable examples:


  1. Trastuzumab (Herceptin): Trastuzumab is used in the treatment of breast cancer that overexpresses the HER2/neu receptor. By blocking this receptor, it inhibits the growth of cancer cells and has become a standard therapy for HER2-positive breast cancer.

  2. Bevacizumab (Avastin): Bevacizumab is employed in various cancers, including colorectal, lung, and kidney cancer. It inhibits the formation of new blood vessels in tumors, depriving them of the nutrients they need to grow.

  3. Pembrolizumab (Keytruda) and Nivolumab (Opdivo): These immune checkpoint inhibitors block PD-1, a protein on immune cells that prevents them from attacking cancer cells. They are used in several cancer types, such as melanoma, lung cancer, and kidney cancer, and have shown remarkable efficacy in some patients.

  4. Ipilimumab (Yervoy): Ipilimumab targets CTLA-4, another immune checkpoint protein. It is approved for the treatment of advanced melanoma and has extended survival rates in some patients.

These monoclonal antibodies represent a promising era in cancer therapy, showcasing the potential of precision medicine. Their approval and continued development underscore their importance in improving the lives of cancer patients and advancing our understanding of this complex disease.

image1

c-MET Discovery Subgroup

The c-MET Discovery Subgroup focuses on studying a protein called c-MET, which is super important in cancer. They want to understand how c-MET affects how cancer cells resist treatments like targeted therapies and immunotherapies. They've found that c-MET plays a big role in making the tumor environment friendly to cancer cells by helping them hide from the immune system.

Their research shows that when c-MET is too active, it's linked to a protein called PD-L1, which cancer cells use to protect themselves from the immune system. Also, c-MET seems to change some immune cells from fighting cancer to supporting it, and it helps create more immune cells that suppress the immune response in the tumor.

The subgroup is exploring exciting possibilities. They've been looking at a special antibody called amivantamab, which can target two things: c-MET and EGFR. This antibody seems to help the immune system fight cancer better. This discovery opens doors to new treatments that use both c-MET blocking and immunotherapy, like a double attack against cancer growth and immune suppression.

All in all, this subgroup's research is crucial. It helps us understand how c-MET works in cancer, giving hope for better treatments tailored to each patient. Their dedication to uncovering the mysteries of c-MET in cancer is vital for finding new ways to fight this disease.